Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chemotherapy
100%
Hepatocyte Growth Factor
100%
Stromal Stem Cells
100%
Anti-hepatoma
100%
Non-small Cell Lung Cancer (NSCLC)
42%
Bevacizumab
42%
Tumor
28%
Neutralizing Antibodies
28%
Platinum-based Chemotherapy
28%
Residual Tumor
28%
Stemness Genes
28%
Heterotransplant
28%
Quantitative PCR
14%
Treatment Regimen
14%
Immunohistochemistry
14%
Expression Level
14%
Initial Treatment
14%
Cancer Stem Cells
14%
Wnt Signaling Pathway
14%
Stem Cell Proliferation
14%
Acquired Resistance
14%
Treatment Combination
14%
Chemotherapy Resistance
14%
Chemotherapy Combinations
14%
Stem Cell Population
14%
Stem Cell Maintenance
14%
Notch Pathway
14%
Primary Resistance
14%
Advanced Non-small Cell Lung Carcinoma
14%
Medicine and Dentistry
Malignant Neoplasm
100%
Hepatoma Derived Growth Factor
100%
Stem Cell
100%
Chemotherapy
100%
Non Small Cell Lung Cancer
44%
Tumor
44%
Bevacizumab
33%
Neutralizing Antibody
22%
Xenograft
22%
Platinum
22%
Notch
11%
Immunohistochemistry
11%
Cell Proliferation
11%
Combination Chemotherapy
11%
Cell Population
11%
Wnt Signaling
11%
Vasculotropin
11%
Quantitative Reverse Transcription Polymerase Chain Reaction
11%
Cancer Stem Cell
11%
Immunology and Microbiology
Stem Cell
100%
Lung
57%
Bevacizumab
42%
Neutralizing Antibody
28%
Quantitative Reverse Transcription Polymerase Chain Reaction
14%
Cell Population
14%
Cell Proliferation
14%
Cancer Stem Cell
14%
Vasculotropin
14%
Notch
14%
Wnt Signaling
14%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Chemotherapy Regimens
100%
Non Small Cell Lung Cancer
40%
Bevacizumab
30%
Neutralizing Antibody
20%
Platinum
20%
Vasculotropin
10%